Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Compugen Ltd

CGEN ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$2.41

▲ +0.00%

Market Cap $228.29M · Vol 48.54K

Key Metrics

P/E Ratio

6.64

FWD: N/A

Market Cap

$228.29M

Micro Cap

Div Yield

N/A

Annual dividend

EPS Growth

-169.74%

YoY

RSI (14)

51.81

Momentum

Beta

2.76

vs Market

52W High

$3.24

25.50% below

52W Low

$1.30

86.10% above

Volume

48.54K

Avg 74.65K

P/B

1.41

Price-to-book

ROE

N/A

Return on equity

Free Float

97.90%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Compugen Ltd (CGEN) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CGEN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

+4.78%

-20.46%

+46.06%

YTD

+57.52%

+66.21%

+131.73%

-62.69%

Financials & Valuation

TTM · Annual

Total Revenue	$72.76M
Net Income	$35.34M
Revenue Growth (YoY)	+107.00%
Gross Margin	87.29%
Operating Margin	43.82%
Net Profit Margin	48.57%
ROE	N/A
ROA · ROIC	26.07% · 44.84%

P/E Ratio	6.64
Forward P/E (FY1)	N/A
PEG Ratio	0.01
P/S	1.97
P/B	1.41
P/FCF	4.58
EPS Growth	-169.74%
Outstanding Shares	94.73M

Technical Indicators

50-Day SMA	$2.25
200-Day SMA	$2.10
RSI (14)	51.81
Beta	2.76
52-Week High	$3.24
52-Week Low	$1.30

Volume Today	48.54K
Avg Daily Volume (30D)	74.65K
Relative Volume	0.65x
Volatility (10D)	46.69
Volatility (30D)	47.77
Free Float	97.90%

Analyst Consensus

STRONG BUY

Current Price $2.41

Mean Target $4.60

52W Low$1.30 52W High$3.24

Current

Target

$1.30 $3.24

Current Analyst target

+90.87% upside potential · 5 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S5PQC7

ISINIL0010852080

CountryIsrael

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.